HepaLife™ announced that the company will present new data from ongoing research and development of the artificial liver device technology at the 6th Annual Meeting of the International Society for Stem Cell Research on June 11-14, 2008 at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
Earlier this month HepaLife™ also announced that the company’s proprietary bioartificial liver device successfully demonstrated key liver functions in a model of the human liver failure environment, which now prompts researchers to move toward in vivo animal studies. The ISSCR Annual Meeting brings an elite audience of biotechnology visionaries, researchers and governmental representatives to talk and present findings at the forefront of stem cell research.
The data entitled “Maintenance of hepatic cell function by the PICM-19H Porcine Liver Stem Cell Line cultured in bioartificial liver” will be presented by Neil C. Talbot, PhD, USDA Agricultural Research Service, Animal Biosciences and Biotechnology Lab.
Mr. Frank Menzler, President and CEO of HepaLife™ said, “We are honored to present at the ISSCR Conference. This leading stem cell research meeting is an important forum to discuss HepaLife’s research accomplishments. Our research team has made significant progress on the development of our bioartificial liver device, including our patented PICM-19 liver stem cell line. We very much look forward to sharing new data from our bioartificial liver program with the scientific community.”
Let us hear your thoughts below: